Department of Urology, Hospital Carlos Haya, Malaga, Spain.
Clin Interv Aging. 2009;4:463-72. doi: 10.2147/cia.s3878. Epub 2009 Dec 29.
Many men with erectile dysfunction (ED) also have associated underlying cardiovascular and metabolic conditions, for which they are likely to be taking medication. Therefore, cardiovascular safety and potential drug interactions are two of the major concerns when using PDE-5 inhibitors in these patients. The PDE-5 inhibitor, vardenafil, is characterized by a rapid onset of action, increased duration of erection, high rates of first-dose success and reliable efficacy that can be maintained with continued use. In both clinical trials and real-life observational studies, vardenafil has demonstrated a favorable efficacy and safety profile in men with ED, including those with associated underlying conditions such as diabetes, hypertension and dyslipidemia. Importantly, the concomitant use of medication for these conditions is not associated with any noteworthy changes in the efficacy and safety of vardenafil. The evidence presented in this review supports the use of vardenafil as a first-line treatment for men with ED, including those with underlying conditions.
许多患有勃起功能障碍（ED）的男性也伴有潜在的心血管和代谢疾病，他们可能正在服用相关药物。因此，在这些患者中使用 PDE-5 抑制剂时，心血管安全性和潜在药物相互作用是两个主要关注点。PDE-5 抑制剂伐地那非具有起效迅速、勃起持续时间延长、首次治疗成功率高以及持续使用可保持可靠疗效的特点。在临床试验和真实世界观察性研究中，伐地那非在 ED 男性中表现出良好的疗效和安全性，包括那些伴有潜在疾病（如糖尿病、高血压和血脂异常）的男性。重要的是，同时使用这些疾病的药物治疗并不会对伐地那非的疗效和安全性产生显著影响。本综述提供的证据支持将伐地那非作为 ED 男性的一线治疗药物，包括那些伴有潜在疾病的男性。
